Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $10.8 million.

  • GeneDx Holdings' Cash from Financing Activities fell 2290.95% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.9 million, marking a year-over-year decrease of 728.23%. This contributed to the annual value of $44.2 million for FY2024, which is 7628.73% down from last year.
  • Per GeneDx Holdings' latest filing, its Cash from Financing Activities stood at $10.8 million for Q3 2025, which was down 2290.95% from $346000.0 recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Cash from Financing Activities registered a high of $499.4 million during Q3 2021, and its lowest value of -$2.4 million during Q2 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $346000.0 (2025), whereas its average is $49.8 million.
  • As far as peak fluctuations go, GeneDx Holdings' Cash from Financing Activities soared by 8301125.0% in 2023, and later plummeted by 10529.24% in 2024.
  • Quarter analysis of 5 years shows GeneDx Holdings' Cash from Financing Activities stood at -$1.0 million in 2021, then skyrocketed by 106.32% to $65000.0 in 2022, then skyrocketed by 72366.15% to $47.1 million in 2023, then crashed by 34.14% to $31.0 million in 2024, then crashed by 65.29% to $10.8 million in 2025.
  • Its Cash from Financing Activities stands at $10.8 million for Q3 2025, versus $346000.0 for Q2 2025 and $13.7 million for Q1 2025.